Olgu Sunumu
PDF EndNote BibTex RIS Kaynak Göster

Hemodiyalize Giren Prostat Kanserli Hastada Enzalutamid ile Uzun Süreli Yanıt

Yıl 2022, Cilt 12, Sayı 6, 1033 - 1035, 30.11.2022
https://doi.org/10.16899/jcm.1175879

Öz

Onkolojide daha uzun ve kaliteli bir yaşam sunan güncel tedaviler, kanser ve kronik hastalıkların bir arada görüldüğü vakaların artmasına neden olmaktadır. İkinci nesil bir anti-androjen ajan olan enzalutamid, metastatik kastrasyona dirençli prostat kanseri (mCRPC) tedavisi için 2012 yılında ABD Gıda ve İlaç Dairesi (FDA) tarafından onaylanmıştır. Son dönem böbrek hastalığı (SDBH) olan hastalarda enzalutamid kullanımına ilişkin çok sayıda hasta içeren bir seri bulunmamaktadır. Bu çalışmada, dosetaksel ile progresyon sonrası yaklaşık 5 yıldır enzalutamid tedavisi ile takip edilen ve haftada 3 gün hemodiyalize giren mCRPC tanılı bir hastayı sunuyoruz.

Kaynakça

  • 1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol [Internet]. 2021 Feb 1 [cited 2022 Aug 19];79(2):243–62. Available from: https://pubmed.ncbi.nlm.nih.gov/33172724/
  • 2. Seok Han K, Joon Hong S. Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer. Yonsei Med J [Internet]. 2015;56:368. Available from: http://dx.doi.org/10.3349/ymj.2015.56.2.368
  • 3. Takimoto T, Nakabori T, Osa A, Morita S, Terada H, Oseto S, et al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.
  • 4. Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial Running title: Enzalutamide and visceral mets in AFFIRM.
  • 5. Schwartz GG. Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases. Cancer Epidemiol Biomarkers Prev [Internet]. 2008 Mar 1 [cited 2022 Sep 13];17(3):478–83. Available from: https://aacrjournals.org/cebp/article/17/3/478/11031/Prostate-Cancer-Serum-Parathyroid-Hormone-and-the
  • 6. Tarhan F, Orçun A, Küçükercan I, Çamursoy N, Kuyumcuoǧlu U. Effect of hemodialysis on serum complexed prostate-specific antigen levels. Scand J Urol Nephrol [Internet]. 2007 [cited 2022 Sep 11];41(5):382–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17853041/
  • 7. Singh Z, Holt SK, Gore JL, Nyame YA, Wright JL, Schade GR. Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation. Eur Urol Open Sci. 2022 May 1;39:79–82.
  • 8. van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, et al. Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. Clin Genitourin Cancer. 2019;17(2):e383–6.
  • 9. Simões J, Augusto I, Meireles S, Vendeira L, Silva C. Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis. 2018; Available from: http://dx.doi.org/10.4322/acr.2018.011
  • 10. Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. Eur Urol Oncol. 2019 Nov 1;2(6):677–84.

Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis

Yıl 2022, Cilt 12, Sayı 6, 1033 - 1035, 30.11.2022
https://doi.org/10.16899/jcm.1175879

Öz

Current therapies in oncology that offer a longer and better quality of life are leading to more cases where cancer and chronic diseases coexist. Enzalutamide, a second-generation anti-androgen agent, was approved by the US Food and Drug Administration (FDA) in 2012 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There is no series with many patients on the use of enzalutamide in patients with end-stage renal disease (ESRD). We present a patient diagnosed with mCRPC who was followed up with enzalutamide treatment for about 5 years after progression with docetaxel and who was on hemodialysis 3 days a week.

Kaynakça

  • 1. Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol [Internet]. 2021 Feb 1 [cited 2022 Aug 19];79(2):243–62. Available from: https://pubmed.ncbi.nlm.nih.gov/33172724/
  • 2. Seok Han K, Joon Hong S. Exponential Rise in Prostate-Specific Antigen (PSA) during Anti-Androgen Withdrawal Predicts PSA Flare after Docetaxel Chemotherapy in Patients with Castration-Resistant Prostate Cancer. Yonsei Med J [Internet]. 2015;56:368. Available from: http://dx.doi.org/10.3349/ymj.2015.56.2.368
  • 3. Takimoto T, Nakabori T, Osa A, Morita S, Terada H, Oseto S, et al. Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients.
  • 4. Loriot Y, Fizazi K, De Bono JS, Forer D, Hirmand M, Scher HI. Enzalutamide in Castration-Resistant Prostate Cancer Patients With Visceral Disease in the Liver and/or Lung: Outcomes From the Randomized Controlled Phase 3 AFFIRM Trial Running title: Enzalutamide and visceral mets in AFFIRM.
  • 5. Schwartz GG. Prostate Cancer, Serum Parathyroid Hormone, and the Progression of Skeletal Metastases. Cancer Epidemiol Biomarkers Prev [Internet]. 2008 Mar 1 [cited 2022 Sep 13];17(3):478–83. Available from: https://aacrjournals.org/cebp/article/17/3/478/11031/Prostate-Cancer-Serum-Parathyroid-Hormone-and-the
  • 6. Tarhan F, Orçun A, Küçükercan I, Çamursoy N, Kuyumcuoǧlu U. Effect of hemodialysis on serum complexed prostate-specific antigen levels. Scand J Urol Nephrol [Internet]. 2007 [cited 2022 Sep 11];41(5):382–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17853041/
  • 7. Singh Z, Holt SK, Gore JL, Nyame YA, Wright JL, Schade GR. Aggressive Prostate Cancer at Presentation Following Solid Organ Transplantation. Eur Urol Open Sci. 2022 May 1;39:79–82.
  • 8. van Nuland M, Groenland S, Bergman AM, Rotmans JI, Rosing H, Beijnen JH, et al. Plasma Levels of Enzalutamide and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer Undergoing Hemodialysis. Clin Genitourin Cancer. 2019;17(2):e383–6.
  • 9. Simões J, Augusto I, Meireles S, Vendeira L, Silva C. Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis. 2018; Available from: http://dx.doi.org/10.4322/acr.2018.011
  • 10. Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, et al. Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial. Eur Urol Oncol. 2019 Nov 1;2(6):677–84.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Bilimleri ve Hizmetleri
Bölüm Olgu Sunumu
Yazarlar

Özge KAMA BAŞCI> (Sorumlu Yazar)
Balikesir State Hospital
0000-0002-2755-6768
Türkiye


Ferhat EKİNCİ>
Şırnak Devlet Hastanesi
0000-0002-9317-942X
Türkiye


Gonca AKDERE ATEŞ>
MANISA CELAL BAYAR UNIVERSITY, SCHOOL OF MEDICINE
0000-0003-0373-7561
Türkiye


Atike Pinar ERDOĞAN>
MANISA CELAL BAYAR UNIVERSITY, SCHOOL OF MEDICINE
0000-0003-4859-7574
Türkiye


Ahmet DİRİCAN>
İZMİR EKONOMİ ÜNİVERSİTESİ, TIP FAKÜLTESİ
0000-0001-6992-9289
Türkiye

Destekleyen Kurum Destekleyen kurum bulunmamaktadır
Proje Numarası -
Erken Görünüm Tarihi 1 Ekim 2022
Yayımlanma Tarihi 30 Kasım 2022
Kabul Tarihi 19 Eylül 2022
Yayınlandığı Sayı Yıl 2022, Cilt 12, Sayı 6

Kaynak Göster

AMA Kama Başcı Ö. , Ekinci F. , Akdere Ateş G. , Erdoğan A. P. , Dirican A. Prolonged Response with Enzalutamide in a Prostate Cancer Patient on Hemodialysis. J Contemp Med. 2022; 12(6): 1033-1035.